Nuo Therapeutics, Inc. (AURX) Free cash flow 2019–2025
Nuo Therapeutics, Inc. (AURX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$1.1MFY2025 · since FY2019: -$921,674 → -$1.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$1.1M | +52.2% |
| FY2024 | -$2.4M | +24.8% |
| FY2023 | -$3.2M | +15.7% |
| FY2022 | -$3.8M | -3039.6% |
| FY2021 | -$119,955 | -122.9% |
| FY2020 | -$53,821 | +94.2% |
| FY2019 | -$921,674 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Gross marginAURX Operating incomeAURX Operating marginAURX Operating cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →